ZD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. ZD is technically near support after a sharp drop, but the setup lacks a strong proprietary buy signal and fundamentals/Street sentiment have recently deteriorated (loss in 2025/Q3, margin compression, and multiple price-target cuts). For an impatient buyer, the risk/reward is not compelling enough at current levels to call it an immediate buy.
Price/Trend: ZD closed at 37.04 (-3.48%) and is trading below the pivot (38.899) and just under S1 support (37.25), with the next support at S2 (36.232). A clean bounce would typically require reclaiming ~38.90 and then holding above ~40.55 (R1). Momentum: MACD histogram is positive (0.0898) but contracting, implying upside momentum is fading rather than accelerating. RSI(6) at 46.5 is neutral—no oversold snapback signal yet. Moving averages: Structure remains bullish (SMA_5 > SMA_20 > SMA_200), suggesting the broader trend isn’t broken, but today’s selloff puts the stock in a vulnerable ‘test support’ zone. Pattern-based expectation: Similar-pattern stats imply ~70% chance of a small dip next day (-0.46%), but a constructive skew over 1 week (+5.19%) and 1 month (+11.97%); that’s supportive for a swing idea, but timing/entry is not ideal immediately after a breakdown day.
News/Execution: RetailMeNot refresh + AI-powered shopping assistant and consolidation into “The RetailMeNot Group” are positive product/brand initiatives that could help engagement and monetization over time.
Flows: Hedge funds are reported as net buyers, with buying amount up ~319% over the last quarter.
Potential corporate action: Analysts note possible value-unlock catalysts via divestitures (timing uncertain).
Upcoming event: QDEC 2025 earnings on 2026-02-23 (after hours) can act as a catalyst if results/guidance stabilize.
with sharp YoY deterioration and gross margin down materially, which is consistent with ‘headwinds’ commentary.
Latest quarter (2025/Q3): Revenue rose to $363.711M (+2.87% YoY), but profitability deteriorated sharply: net income fell to -$3.598M (-92.59% YoY), EPS to -0.09 (-91.89% YoY), and gross margin dropped to 69.63 (down ~18.02% YoY). This is a ‘low growth + margin pressure’ snapshot—revenue held up modestly, but earnings quality weakened meaningfully.
Recent trend: Ratings stayed Neutral/Equal Weight, but price targets were cut across the board (Citi to $35 from $42; Barclays to $34 from $40; UBS to $38 from $40). That’s a clear negative revision cycle. Wall Street pros: Possible value unlock via divestitures; inbound interest in parts of the portfolio; longer-term optionality if assets are monetized. Wall Street cons: Softer Q3 results and implied continued Q4 headwinds; limited visibility/timing on divestitures; expectation of only mid-single-digit EBITDA growth without major asset sales. Influential/politician activity: No recent Congress trading data available in the last 90 days; no notable insider buying trend reported.
